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1748-6815/ª 2014 British Association of PSummary Use of human acellular dermal matrix (ADM) during prosthetic breast reconstruc-
tion has increased. Several ADM products are available produced by differing manufacturing
techniques. It is not known if outcomes vary with different products. This study reports the
complication prevalence following use of a tutoplast-derived ADM (T-ADM) in prosthetic breast
reconstruction. We performed a retrospective chart review of 203 patients (mean follow-up
times 12.2 months) who underwent mastectomy and immediate prosthetic breast reconstruc-
tion utilizing T-ADM, recording demographic data, surgical indications and complication (infec-
tion, seroma, hematoma, wound healing exceeding three weeks and reconstruction failure).
During a four-year period, 348 breast reconstructions were performed Complications occurred
in 16.4% of reconstructed breasts. Infection occurred in 6.6% of breast reconstructions (3.7% e
major infection, requiring intravenous antibiotics and 2.9% minor infection, requiring oral an-
tibiotics only). Seromas occurred in 3.4% and reconstruction failure occurred in 0.6% of breast
reconstructions. Analysis suggested that complication prevalence was significantly higher in
patients with a BMI >30 (pZ 0.03). The complication profile following T-ADM use is this series
is comparable to that reported for with other ADM products. T-ADM appears to be a safe and
acceptable option for use in ADM-assisted breast reconstruction.
ª 2014 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by
Elsevier Ltd. All rights reserved.University HealthSystem, Division of Plastic Surgery, 501 Skokie Blvd, Northbrook, IL 60062, USA. Tel.:
ore.org (M.A. Howard).
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1346 V.L.M. Rundell et al.IntroductionThe percentage of mastectomy patients who receive a
prosthetic breast reconstruction is between 15 and 30%.1,2
Implant-based reconstruction remains the most common
reconstructive technique.3 To improve clinical outcomes of
prosthetic breast reconstruction, there has been an
increased use of acellular dermal matrix (ADM). The re-
ported benefits of ADM include: facilitating implant posi-
tioning in immediate or delayed reconstruction, simplified
two-stage tissue expander-implant (TE/I) reconstruc-
tion,4,5 improved control of the inframammary fold (IMF)
and lower-pole fullness, shortened or eliminated need for
subsequent tissue expansion, and increased options for
direct-to-implant (DTI) or “one-stage” reconstruction.6
A major concern regarding ADM use in breast recon-
struction is the potential for increased complications. Sin-
gle institution reports provide conflicting information7e9
and recent meta-analyses10e13 suggest that prevalence of
complication of ADM is increased though no particular ADM
products were specified. An understanding of the preva-
lence of infection, and the outcomes of patients receiving
post-mastectomy radiation therapy (PMRT) following ADM
implantation are useful as these events may impact re-
sults7,14 [See also, Table 1]. Several dermal matrix products
are available15e21 and questions exist as to the impact of
differing product manufacturing techniques upon the
product performance and patient outcomes.22 The most
studied ADM is AlloDerm (LifeCell Corp, Branchburg, NJ), an
aseptically produced dermal matrix product, other ADM
products have been less well studied.15e22
AlloMax Surgical Graft (C. R. Bard/Davol Inc, Warwick,
RI), is a human derived ADM which undergoes the
TutoPlast Process preparation, of solvent dehydration
cleaning and preservation process.22 This yields a sterile
and virally inactivated, rather than aseptic, product.
We report the prevalence of post-implant complica-
tions following use of Tutoplast-derived ADM (T-ADM) in
prosthetic breast reconstruction, and the complication
profiles of two different ADM recipient patient populations
based on indication for surgery: risk-reduction versus
oncologic presentation. Further, we compare these results
to reports made of patients implanted with aseptically-
prepared ADM.
Patients and methods
The Institutional Review Board at NorthShore University
HealthSystem approved this retrospective review of all
patients undergoing immediate breast reconstruction
using T-ADM-assisted two-stage (tissue-expander/implant)
or one-stage (direct-to-implant) technique between
January 2007 and December 2010. TutoPlast processed
human dermis (RTI Biologics, Alachua, FL) was utilized,
initially under the trade name NeoForm (Mentor Corp,
Santa Barbara, CA) and subsequently under the trade
name AlloMax due to a change in commercial licensing.
Fellowship-trained surgical oncologists performed all
mastectomies and board-certified plastic surgeons per-
formed all reconstructions in a single academic healthcare
system.The method of T-ADM reconstruction was identical to
that described by others5,6 in order to create a defined
inframammary fold and a stable pocket for placement of
the expander/implant. After completion of the mastec-
tomy, the breast skin flaps were inspected for adequate
vascularity and hemostasis. The pectoralis major muscle
was elevated from the chest wall and its costal origins,
creating a submuscular pocket in the upper portion of the
reconstruction. To cover the lower pole of the implant,
allograft was hydrated and sutured to the chest wall, in a
curvilinear path along the planned internal IMF. The leading
edge of allograft was sutured to the inferior edge of the
pectoralis. The implant (a tissue expander in two-stage
reconstructions or a smooth round saline sizer in one-
stage reconstructions) was placed in the space and the
pocket closed temporarily to ensure correct device size. In
one-stage reconstructions, the sizer was removed and the
final implant placed into the pocket. The skin was sutured
closed over a drain. Patients were prescribed prophylactic
oral antibiotics until the drains were removed once
drainage was consistently 30 cc or less per drain in a 24 h
period.
Chart review abstracted age, patient co-morbidities
(including history of radiation and chemotherapy), surgi-
cal procedure type, and occurrence of complications,
independently assessed by two investigators (VLMR and
RTB). When there was lack of consensus, the chart was
reviewed by a third investigator (MAH). The outcome data
were analyzed for specific patient risk factors and associ-
ated complications. Identified complications were: infec-
tion, hematoma, seroma (a loculated, symptomatic fluid
collection requiring aspiration or drain placement), flap
loss, delayed wound healing (wounds lasting >3 weeks) and
reconstruction failure (implant removal). Infection was
defined as ‘major’ if intravenous antibiotics, hospitaliza-
tion, and/or surgical debridement were required and
‘minor’ if oral antibiotic therapy alone was used.
We defined “risk-reduction” as mastectomy performed
for a patient who did not have an active cancer diagnosis
(eg. BRCAþ or had completed all treatments for the breast
cancer). An “oncologic” patient indication included mas-
tectomy performed for treatment of an active breast can-
cer and a contralateral mastectomy for risk-reduction).
These patients have different therapeutic profiles, which
may influence complications. As such the data is reported
in aggregate, and also following segregation. The preva-
lence of complications is reported as both per patient (PP)
and per reconstruction (PR) to facilitate comparison with
prior studies.
Data were analyzed using SPSS 15.0, (IBM Corp., Chi-
cago, IL). Continuous data such as age (at time of mas-
tectomy) and length of follow-up (in months) were reported
as mean (SD) while categorical data such as surgical pro-
cedure type and occurrence of complications were re-
ported as count and percentage. Student’s T-test (for
continuous variables) and chi-square or Fisher exact tests
(for categorical variables) were used to determine the
significance of difference between risk-reduction and
oncologic patients. We conducted univariate and multi-
variate logistic regression analyses to determine the inde-
pendent risk factors of postoperative complications. For
each analysis, preoperative (patient demographics and co-
Table 1 Previous studies reporting complications in breast reconstruction facilitated by ADM use.
Author Type n Overall
complications
(%)
Infection (%) Seroma (%) Radiation Hx No radiation
Antony, 201025 2 stage
reconstruction
96 women 153
breasts
(23.6) (7.2) (7.2) a a
Bindingnavale,
200726
2 stage
reconstruction
41 women 65
breasts
7/65 (10.8) 2/65 (3.1) 3/65 (4.6) 1/5 (20) 6/41 (14.7)a
Brooke, 201218
AlloDerm
Mostly 2 stage
reconstruction
29 women 49
breasts
11/49 (22) 5/49 (10) a a a
DermaMatrix 64 women 110
breasts
16/110 (15) 11/110 (10) a a a
Flex HD 38 women 62
breasts
10/62 (16) 6/62 (10) a a a
Gamboa-
Bobadilla,
200627
single and 2-
stage
reconstruction
11 women 13
breasts
1/11 (9.0) 1/11 (9.0) 1/11 (9.0) 0/2 (0) 1/9 (11)
Lanier, 20108 2 stage
reconstruction
119 women 75
breastsb 52
breastsc
17/75 (22.7)b
24/52 (46.2)c
9/75 (12.0)b
15/52
(28.9)c
5/75 (6.7)b
8/52 (15.4)c
a a
Liu, 20119 Mostly 2 stage
reconstruction
151 womenb
204 breastsb
192 womenc
266 breastsc
25/204 (12.3)b
52/266 (19.5)c
5/204 (2.5)b
18/266
(6.8)c
8/204 (3.9)b
19/266
(7.1)c
a a
Losken, 200820 Mostly 2 stage
reconstruction
22 women 31
breasts
1/31 (3.2) 0/31 (0) 0/31 (0) a a
Nahabedian, 20097 2 stage
reconstruction
285 womenb
376 breastsb 76
womenc 100
breastsc
(w11.0)b 17/
100 (17.0)c
22/376
(5.9)b 5/100
(5.0)c
9/376 (2.4)b
5/100 (5.0)c
Not reported
for non-ADM 8/
23 (34.7)c
Not
reported for
non-ADM
10/77
(13.0)c
Nguyen, 201023 2 stage
reconstruction
163 womenb
246 breastsb 41
womenc 76
breastsc
11/246 (4.5)b
10/75 (13.3)c
7/246 (2.8)b
4/75 (5.3)c
a a a
Salzberg, 201114 Single stage
reconstruction
260 women 466
breasts
(3.9) 1/466 (0.4) a 3/21 (14.3) 15/445 (3.4)
Seth, 201219
Cryopreserved
ADM
2-stage
reconstruction
96 women 136
breasts
26/136 (19.1) 14/136
(10.3)
3/136 (2.2) a a
Pre-hydrated ADM 159 women 233
breasts
45/233 (19.3) 12/233 (5.2) 5/233 (2.1) a a
Spear, 200815 2 stage
reconstruction
43 women 58
breasts
7/58 (12) 4/58 (6.9) 1/58 (1.7) 5/11 (45) 2/47 (4.3)
Weichman,
201317aseptic
ADM
1- and 2-stage
reconstruction
58 women 90
breasts
a 18 (20) 4 (4.4) a a
Ready-to-use ADM 64 women 105
breasts
a 9 (8.5) 1 (1.0) a a
a Unable to determine completely due to lack of data.
b No ADM usage in this population.
c ADM used in this population.
T-ADM in prosthetic breast reconstruction 1347morbidities) and intra-operative (surgical procedure and
reconstruction types) variables showing an association with
postoperative complications at p < 0.1 in the univariate
analysis were included in the multivariate logistic regres-
sion models. Significance is reported for p-values less than
0.05.Results
During the four-year study window, 348 immediate pros-
thetic breast reconstructions were performed in 203 pa-
tients. In 136 patients, the primary indication was for
oncologic treatment while 67 patients were for risk
1348 V.L.M. Rundell et al.reduction. Mean patient age was 48.5 years at the time of
first surgery. The mean length of follow-up was 12.1 months
[Range: 0.2e26.2 months; Median: 10.9 months]. Patient
demographics are shown in Table 2.
Risk-reducing patients had significantly lower rates of
both radiation and chemotherapy as compared with
oncology-present patients. The delivery for these treat-
ments was also different. In risk-reducing patients radia-
tion and chemotherapy were mostly administered pre-
operatively, while oncologic patients received radiation
and chemotherapy at more variable intervals. On the
whole, risk-reducing patients had a higher rate of nipple-
sparing mastectomy and bilateral procedures (Tables 3
and 4).
There were 57 complications in the total study popula-
tion with complications occurring in 28.1% of patients and
16.4% of reconstructed breasts. The most common
complication was infection. Major infections (Per Patient:
6.4%; Per Reconstruction: 3.7%) required IV antibiotic
therapy or re-operation (including graft removal in two
patients) while minor infections (PP: 4.9%; PR: 2.9%)
resolved with oral antibiotics alone. Next most common
complications were seroma and wound healing greater than
3 weeks, which had identical rates (PP: 5.9% PR: 3.4%).
Hematoma, mastectomy flap loss and reconstruction failure
occurred far less frequently. There was no statistical dif-
ferences in complications between the risk reducing and
oncologic patients.Table 2 Population demographics reported as mean (SD) or pre
Risk-reduction only
Age (in years at time of surgery) 42.0 (10.1)
Length of follow-up (months) 11.1 (7.9)
Median length of follow-up (months) 9.8
Range length of follow-up (months) 0.2e28
BMI  SD 22.7 (4.0)
Co-morbiditiesd
Diabetes mellitus 1 (1.5%)
Tobacco use (current) 2 (2.9%)
Tobacco use (former) 17 (25.3%)
Alcohol use (occasional) 50 (74.6%)
Risk/markers
Positive family history 26 (38.8%)
BRCAþ 36 (53.4%)
Adjuvant therapy
Radiation 2 (2.9%)
Chemotherapy 4 (6.0%)
Number of proceduresa 132
Total mastectomy 57 (43%)
Modified radical mastectomy 0
Nipple-sparing mastectomy 75 (57%)
Reconstructionsa 132
One-stage 109 (83%)
Two-stage 23 (17%)
a Reflects the number of breasts treated by each type of mastectom
b p is significant as measured by t-Test.
c p is significant as measured by Pearson c2.
d Patient can have multiple co-morbidities.Analysis suggested that elevated BMI (ORZ 1.07, 95% CI
1.01e1.13, p Z 0.03) was associated with higher risk of
post-operative complications. However, with multivariable
analysis after controlling for age and reconstruction type,
BMI was no longer statistically significant.
There were too few instances of radiation or chemo-
therapy in the risk reducing population to compare with the
oncologic population. Within the oncologic patients, there
was no significant interaction between complication
occurrence and either radiation or chemotherapy. Like-
wise, history of smoking, diabetes, and alcohol usage were
not correlated with increased complications in either
group.Discussion
We examined our complications following use of Tutoplast-
derived acellular dermal matrix (T-ADM) used with pros-
thetic breast reconstruction. Following 348 placements of
T-ADM in 203 patients, complications (infection, seroma,
hematoma, or delayed wound healing) occurred in 16.4% of
breast reconstructions. Infection, which may lead to
explantation and “reconstruction failure” occurred in 6.6%
of T-ADM breast reconstructions. We divided infection into
major and minor infection based on the severity of pre-
sentation and treatment required. Major infection was
defined as requiring surgical management or IV antibioticsvalence (percentage).
(N Z 67) Oncologic Hx (N Z 136) p Value
51.9 (10.5) <0.00b
12.6 (7.3) 0.170
11.3
0.2e26.2
24.8 (5.3) 0.004b
11 (8.1%) 0.109
6 (4.4%) 1.000
31 (22.8%) 0.862
95 (69.9%) 0.480
36 (26.5%) 0.077
15 (11.0%) <0.001c
37 (27.2%) <0.001c
65 (47.8%) <0.001c
216
155 (72%) <0.001c
16 (7%)
45 (21%)
216
108 (50%) <0.001c
108 (50%)
y procedure.
Table 3 Complications observed in patients with Allomax-assisted breast reconstruction patients. Total cohort, and separated
based on presence of malignancy.
Events Incidence
(% per
patient)a
Incidence
(% per
reconstruction)b
Events in
risk-reducing
cases (% of
reconstructions)c
Events in oncologic
cases (% of
reconstructions)d
Odds
ratio
95% CI p Value
Seroma 12 5.9 3.4 4 (3.0) 8 (3.7) 1.23 0.36e4.17 0.78
Hematoma 4 2.0 1.1 1 (0.8) 3 (1.4) 1.84 0.19e17.9 1.00
InfectiondMajor 13 6.4 3.7 3 (2.3) 10 (4.6) 2.09 0.57e7.7 0.38
InfectiondMinor 10 4.9 2.9 2 (1.5) 8 (3.7) 2.5 0.52e12.0 0.33
Delayed wound healing 12 5.9 3.4 7 (5.3) 5 (2.3) 0.42 0.13e1.36 0.22
Mastectomy flap loss 4 2.0 1.1 0.0 4 (1.9) inf inf 0.17
Reconstruction failure 2 1.0 0.6 0.0 2 (0.9) inf inf 0.53
Total 57 28.1 16.4 17 (12.9) 40 (18.5) 1.59 0.86e2.9 0.14
a Total number of patients in this population is 203.
b Total number of reconstructions in this population is 348.
c Total number of reconstructions in this population is 132.
d Total number of reconstructions in this population is 216.
T-ADM in prosthetic breast reconstruction 1349and/or further surgical management occurred in 3.7% of
breast reconstructions. This differs from others studies that
report infection without describing severity8 or those who
specify cases which require IV antibiotics or explanta-
tion.14,18,23 Further, the overall infection occurrence in this
series was lower17e19 or comparable7,9,15,23 to other re-
ported series. Of the thirteen major infections, nine were
cellulitis with no documented pathogen, and one each of
candida parapsilosis, pseudomonas, staphylococcus, and
MRSA. No minor infection patient had a positive culture, nor
did any have reconstruction failure. Thus, some of these
may represent seroma or inflammatory response to the T-
ADM, commonly referred to as “the red breast syndrome”.
Hence, the true prevalence of infection may be closer to
that of the major infection prevalence of 3.9% and suggests
that the T-ADM infection profile is similar to others previ-
ously reported.8,18 Recently, Weichman and colleagues17
compared reconstructions with ready-to-use versus
aseptic acellular dermal matrix, and while they found a
decrease in overall infection (8.5 percent versus 20.0
percent; pZ 0.0088), they found no statistically significant
difference in either major infection (4.7 percent versus
12.2 percent; p Z 0.069), or need for explantation (1.9
percent versus 6.6 percent; p Z 0.1470) between their
groups.Table 4 Univariate and multivariable logistic regression on any
Predictor Univariate
OR 95%CI
Risk-reducing vs. oncologic 0.82 0.42e1.58
Age (in years at time of surgery) 1.03 0.99e1.05
BMI > 30 (kg/m2) 1.07 1.01e1.13
Type of mastectomy
Modified radical vs. total 0.72 0.19e2.76
Nipple-sparing vs. total 0.86 0.44e1.67
One-stage vs. two-stage 0.57 0.31e1.05
a Variables with p < 0.1 in the univariate analysis were included in t
vs oncologic) was included in the multivariable as it is our main compThe prevalence of complications and infections in our
series is similar to reports of alternative ADM products7,21 as
well as the meta-analyses of ADM-assisted breast recon-
struction reports.10,15 Kim et al.10 found a 15.4% overall
prevalence of surgical complications and an increase in the
pooled risk of infection from 4.7% (no ADM implant recon-
struction) to 5.3% (with ADM) and a relative risk of infection
with ADM of 2.47 (95% confidence interval, 1.71e3.57)
compared to no ADM. Likewise, Newman et al.12 reported
12% overall prevalence of complications with infection
(5.6%) and seroma (3.3%) being the most frequent compli-
cations. We have no definitive reason explanation for the
lower prevalence of complications in one-stage versus two-
stage reconstruction cohorts. However, this may be due to
selection bias as patients undergoing one-stage recon-
struction were required to be healthy and smaller-
breasted.
Our univariate analysis suggested that patients with
elevated BMI had increased complications, similar to
studies of aseptic-ADM.9 We did not find an association
between tobacco use (either former or current) with
increased complications. However, the prevalence of
smoking in our patient population (3.9% current, 23.7%
former) may not be high enough to demonstrate an effect.
Finally, we saw no impact of diabetes on complicationcomplications.
Multivariablea
p value OR 95%CI p value
0.547 1.38 0.63e3.01 0.424
0.063 1.02 0.99e1.05 0.193
0.031 1.05 0.99e1.12 0.101
0.628 e e e
0.656 e e e
0.072 0.57 0.29e1.10 0.095
he multivariable analysis. Patient population group (risk-reducing
arison of interest.
1350 V.L.M. Rundell et al.development in our study, but this may be because the
percentage of diabetes patients in this population was less
than 10%.
The effect of radiation therapy on the prevalence of
complications is unsettled.14,15,23,24 We did not find a
higher prevalence of complications with radiation therapy.
This finding could be due to the small population of radi-
ated patients in the study and selection bias. We recognize
the risk for complications may increase in previously irra-
diated patients. If previously irradiated patients have signs
of radiation injury, (i.e.: substantial skin changes or tight
skin/muscle envelope) we favor autologous reconstruction.
Further, patients who undergo post mastectomy radiation
generally do so following chemotherapy treatment weeks
or months after initial mastectomy and allograft place-
ment. Thus, one would expect the allograft to be fully
incorporated and behave similarly to non-allograft, vascu-
larized tissue. Our study was not designed to compare post-
mastectomy radiation outcomes in allograft vs. total sub-
muscular patient reconstruction populations.
The limitations of our study include it being an un-
matched retrospective study with selection bias, our not
evaluating aesthetic results, patient reported outcomes, or
economics.
In conclusion, our use of Tutoplast-derived acellular
dermal matrix in prosthetic breast reconstruction demon-
strated similar complication prevalence to other ADM
products used today. As such, this product can be consid-
ered when an ADM is needed with prosthetic breast
reconstruction.Ethical approval
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